[
  {
    "id": "rn-q-001",
    "scope": ["RN"],
    "medicationId": "rn-001",
    "medication": "Quinidine",
    "questionType": "multiple-choice",
    "stem": "Which assessment finding in a patient taking quinidine requires immediate notification of the provider?",
    "choices": [
      "Mild nausea",
      "Excessive diarrhea",
      "Occasional dizziness",
      "Dry mouth"
    ],
    "correctAnswer": "Excessive diarrhea",
    "rationale": "Excessive diarrhea is a sign of quinidine toxicity and may precede serious cardiac dysrhythmias.",
    "clinicalPearl": "GI symptoms are often the earliest warning sign of quinidine toxicity."
  },
  {
    "id": "rn-q-002",
    "scope": ["RN"],
    "medicationId": "rn-002",
    "medication": "Procainamide",
    "questionType": "select-all-that-apply",
    "stem": "Which findings suggest a potential adverse reaction to procainamide? (Select all that apply.)",
    "choices": [
      "Joint pain",
      "Butterfly-shaped facial rash",
      "Hypotension",
      "Bradycardia",
      "Dry cough"
    ],
    "correctAnswer": [
      "Joint pain",
      "Butterfly-shaped facial rash",
      "Hypotension"
    ],
    "rationale": "Procainamide can cause a lupus-like syndrome and hypotension.",
    "clinicalPearl": "Drug-induced lupus is a well-known complication of procainamide therapy."
  },
  {
    "id": "rn-q-003",
    "scope": ["RN"],
    "medicationId": "rn-003",
    "medication": "Lidocaine",
    "questionType": "multiple-choice",
    "stem": "Which assessment finding is most concerning in a patient receiving IV lidocaine?",
    "choices": [
      "Metallic taste",
      "Mild nausea",
      "Confusion and tremors",
      "Injection site discomfort"
    ],
    "correctAnswer": "Confusion and tremors",
    "rationale": "Neurologic symptoms indicate lidocaine toxicity and may precede seizures.",
    "clinicalPearl": "CNS toxicity occurs before cardiovascular collapse with lidocaine."
  },
  {
    "id": "rn-q-004",
    "scope": ["RN"],
    "medicationId": "rn-005",
    "medication": "Flecainide",
    "questionType": "multiple-choice",
    "stem": "Flecainide is contraindicated in patients with which condition?",
    "choices": [
      "Atrial fibrillation",
      "Structural heart disease",
      "Hypertension",
      "Sinus tachycardia"
    ],
    "correctAnswer": "Structural heart disease",
    "rationale": "Class IC agents increase mortality in patients with structural heart disease.",
    "clinicalPearl": "Class IC antidysrhythmics are powerful but dangerous in damaged myocardium."
  },
  {
    "id": "rn-q-005",
    "scope": ["RN"],
    "medicationId": "rn-007",
    "medication": "Esmolol",
    "questionType": "multiple-choice",
    "stem": "Why is esmolol preferred for short-term rate control in acute settings?",
    "choices": [
      "It has oral availability",
      "It has a long half-life",
      "It has a very short half-life",
      "It causes less hypotension than other beta-blockers"
    ],
    "correctAnswer": "It has a very short half-life",
    "rationale": "Esmolol’s rapid onset and short duration allow quick titration and discontinuation.",
    "clinicalPearl": "Esmolol is ideal when rapid beta-blockade reversal may be needed."
  },
  {
    "id": "rn-q-006",
    "scope": ["RN"],
    "medicationId": "rn-012",
    "medication": "Amiodarone",
    "questionType": "select-all-that-apply",
    "stem": "Which teaching points should be included for a patient starting amiodarone? (Select all that apply.)",
    "choices": [
      "Avoid grapefruit products",
      "Report vision changes",
      "Monitor for thyroid dysfunction",
      "Take medication with high-fat meals",
      "Expect urine discoloration"
    ],
    "correctAnswer": [
      "Avoid grapefruit products",
      "Report vision changes",
      "Monitor for thyroid dysfunction"
    ],
    "rationale": "Amiodarone affects thyroid, eyes, and has major CYP interactions with grapefruit.",
    "clinicalPearl": "Amiodarone affects multiple organ systems—ongoing monitoring is essential."
  },
  {
    "id": "rn-q-009",
    "scope": ["RN"],
    "medicationId": "rn-009",
    "medication": "Atenolol",
    "questionType": "multiple-choice",
    "stem": "Which assessment finding would require holding atenolol and notifying the provider?",
    "choices": [
      "Blood pressure 138/84 mmHg",
      "Heart rate 52 bpm",
      "Mild fatigue",
      "Occasional headache"
    ],
    "correctAnswer": "Heart rate 52 bpm",
    "rationale": "Atenolol can cause bradycardia; heart rates below 60 bpm warrant provider notification.",
    "clinicalPearl": "Always assess apical pulse before administering beta blockers."
  },
  {
    "id": "rn-q-010",
    "scope": ["RN"],
    "medicationId": "rn-010",
    "medication": "Propranolol",
    "questionType": "multiple-choice",
    "stem": "Why should propranolol be used cautiously in patients with asthma?",
    "choices": [
      "It increases mucus production",
      "It blocks beta-2 receptors causing bronchoconstriction",
      "It prolongs the QT interval",
      "It causes excessive sedation"
    ],
    "correctAnswer": "It blocks beta-2 receptors causing bronchoconstriction",
    "rationale": "Propranolol is nonselective and may worsen bronchospasm by blocking beta-2 receptors.",
    "clinicalPearl": "Nonselective beta blockers increase respiratory risk in asthma and COPD."
  },
  {
    "id": "rn-q-011",
    "scope": ["RN"],
    "medicationId": "rn-011",
    "medication": "Bisoprolol",
    "questionType": "multiple-choice",
    "stem": "Which patient teaching is most important for someone prescribed bisoprolol?",
    "choices": [
      "Limit potassium-rich foods",
      "Do not abruptly stop the medication",
      "Take the medication at bedtime only",
      "Expect increased appetite"
    ],
    "correctAnswer": "Do not abruptly stop the medication",
    "rationale": "Abrupt discontinuation of beta blockers may cause rebound tachycardia and hypertension.",
    "clinicalPearl": "Beta blockers should always be tapered, not stopped suddenly."
  },
  {
    "id": "rn-q-012",
    "scope": ["RN"],
    "medicationId": "rn-012",
    "medication": "Amiodarone",
    "questionType": "select-all-that-apply",
    "stem": "Which findings should be reported immediately in a patient taking amiodarone? (Select all that apply.)",
    "choices": [
      "Blurred vision",
      "Weight gain",
      "Shortness of breath",
      "Photosensitivity",
      "Dry skin"
    ],
    "correctAnswer": [
      "Blurred vision",
      "Shortness of breath"
    ],
    "rationale": "Amiodarone can cause pulmonary toxicity and ocular changes.",
    "clinicalPearl": "Amiodarone affects multiple organs—lungs, thyroid, liver, and eyes."
  },
  {
    "id": "rn-q-013",
    "scope": ["RN"],
    "medicationId": "rn-013",
    "medication": "Dronedarone",
    "questionType": "multiple-choice",
    "stem": "Which medication interaction is most concerning when administering dronedarone?",
    "choices": [
      "Acetaminophen",
      "Digoxin",
      "Ibuprofen",
      "Aspirin"
    ],
    "correctAnswer": "Digoxin",
    "rationale": "Dronedarone increases digoxin levels, raising the risk of toxicity.",
    "clinicalPearl": "Always review cardiac drug combinations for additive effects."
  },
  {
    "id": "rn-q-014",
    "scope": ["RN"],
    "medicationId": "rn-014",
    "medication": "Dofetilide",
    "questionType": "multiple-choice",
    "stem": "Why must dofetilide initiation occur in a monitored setting?",
    "choices": [
      "Risk of hypotension",
      "Risk of renal failure",
      "Risk of torsades de pointes",
      "Risk of severe bradycardia"
    ],
    "correctAnswer": "Risk of torsades de pointes",
    "rationale": "Dofetilide prolongs QT interval and may precipitate torsades de pointes.",
    "clinicalPearl": "QT monitoring is mandatory with Class III antiarrhythmics."
  },
  {
    "id": "rn-q-015",
    "scope": ["RN"],
    "medicationId": "rn-015",
    "medication": "Ibutilide",
    "questionType": "multiple-choice",
    "stem": "Which electrolyte abnormality increases the risk of ibutilide-induced dysrhythmias?",
    "choices": [
      "Hypernatremia",
      "Hypokalemia",
      "Hypercalcemia",
      "Hypermagnesemia"
    ],
    "correctAnswer": "Hypokalemia",
    "rationale": "Low potassium increases QT prolongation and torsades risk.",
    "clinicalPearl": "Correct electrolytes before administering QT-prolonging drugs."
  },
  {
    "id": "rn-q-016",
    "scope": ["RN"],
    "medicationId": "rn-016",
    "medication": "Sotalol",
    "questionType": "multiple-choice",
    "stem": "Which finding would contraindicate giving sotalol?",
    "choices": [
      "QTc interval of 480 ms",
      "Heart rate 72 bpm",
      "Blood pressure 130/80 mmHg",
      "Mild fatigue"
    ],
    "correctAnswer": "QTc interval of 480 ms",
    "rationale": "Sotalol prolongs QT and increases risk of torsades de pointes.",
    "clinicalPearl": "QTc > 440 ms significantly raises dysrhythmia risk."
  },
  {
    "id": "rn-q-017",
    "scope": ["RN"],
    "medicationId": "rn-017",
    "medication": "Diltiazem",
    "questionType": "multiple-choice",
    "stem": "Which condition would make diltiazem unsafe to administer?",
    "choices": [
      "Atrial fibrillation with RVR",
      "Sick sinus syndrome without pacemaker",
      "Hypertension",
      "Stable angina"
    ],
    "correctAnswer": "Sick sinus syndrome without pacemaker",
    "rationale": "Diltiazem suppresses AV node conduction and may cause severe bradycardia.",
    "clinicalPearl": "AV-node blockers require rhythm awareness."
  },
  {
    "id": "rn-q-018",
    "scope": ["RN"],
    "medicationId": "rn-018",
    "medication": "Verapamil",
    "questionType": "multiple-choice",
    "stem": "Which concurrent medication increases the risk of heart block when given with verapamil?",
    "choices": [
      "Acetaminophen",
      "Metoprolol",
      "Furosemide",
      "Potassium chloride"
    ],
    "correctAnswer": "Metoprolol",
    "rationale": "Combined beta blockers and calcium channel blockers can cause severe bradycardia and heart block.",
    "clinicalPearl": "Avoid stacking AV-node blocking agents unless closely monitored."
  },
  {
    "id": "rn-q-019",
    "scope": ["RN"],
    "medicationId": "rn-008",
    "medication": "Metoprolol",
    "questionType": "multiple-choice",
    "stem": "Which vital sign indicates the need to hold metoprolol and notify the provider?",
    "choices": [
      "Blood pressure 148/92 mmHg",
      "Respiratory rate 20 breaths/min",
      "Heart rate 56 bpm",
      "Temperature 99.2°F (37.3°C)"
    ],
    "correctAnswer": "Heart rate 56 bpm",
    "rationale": "Metoprolol decreases heart rate; a pulse under 60 bpm requires evaluation before administration.",
    "clinicalPearl": "Always check apical pulse for one full minute before beta blockers."
  },
  {
    "id": "rn-q-020",
    "scope": ["RN"],
    "medicationId": "rn-008",
    "medication": "Metoprolol",
    "questionType": "multiple-choice",
    "stem": "A patient taking metoprolol reports new onset of cold fingers and toes. What is the best response?",
    "choices": [
      "Continue medication; this is expected",
      "Hold the dose and notify the provider",
      "Apply warm compresses daily",
      "Increase fluid intake"
    ],
    "correctAnswer": "Hold the dose and notify the provider",
    "rationale": "Cold extremities may indicate decreased peripheral perfusion from excessive beta blockade.",
    "clinicalPearl": "Peripheral vasoconstriction can occur, especially in patients with vascular disease."
  },
  {
    "id": "rn-q-021",
    "scope": ["RN"],
    "medicationId": "rn-008",
    "medication": "Metoprolol",
    "questionType": "select-all-that-apply",
    "stem": "What are priority assessments before administering metoprolol? (Select all that apply.)",
    "choices": [
      "Apical pulse",
      "Blood pressure",
      "Glucose level",
      "Respiratory status",
      "Urine output"
    ],
    "correctAnswer": [
      "Apical pulse",
      "Blood pressure",
      "Respiratory status"
    ],
    "rationale": "Metoprolol depresses cardiac output and may cause bronchospasm; baseline assessment is essential.",
    "clinicalPearl": "Nonselective effects increase respiratory risk in patients with asthma and COPD."
  },
  {
    "id": "rn-q-022",
    "scope": ["RN"],
    "medicationId": "rn-019",
    "medication": "Atropine",
    "questionType": "multiple-choice",
    "stem": "Which symptom indicates effective response to atropine in symptomatic bradycardia?",
    "choices": [
      "Heart rate increases to 70 bpm",
      "Blood pressure decreases to 90/60 mmHg",
      "Respiratory rate decreases",
      "Temperature increases"
    ],
    "correctAnswer": "Heart rate increases to 70 bpm",
    "rationale": "Atropine blocks vagal influence, increasing heart rate.",
    "clinicalPearl": "Atropine does NOT work in third-degree heart block with a ventricular escape rhythm."
  },
  {
    "id": "rn-q-023",
    "scope": ["RN"],
    "medicationId": "rn-019",
    "medication": "Atropine",
    "questionType": "multiple-choice",
    "stem": "Which is the most concerning adverse effect to report for a patient receiving atropine?",
    "choices": [
      "Dry mouth",
      "Blurred vision",
      "Urinary retention",
      "Heart rate 160 bpm"
    ],
    "correctAnswer": "Heart rate 160 bpm",
    "rationale": "Excessive tachycardia increases myocardial oxygen demand and risk for ischemia.",
    "clinicalPearl": "Atropine’s anticholinergic effects impact multiple body systems."
  },
  {
    "id": "rn-q-024",
    "scope": ["RN"],
    "medicationId": "rn-020",
    "medication": "Digoxin",
    "questionType": "multiple-choice",
    "stem": "Which finding suggests digoxin toxicity?",
    "choices": [
      "Weight gain",
      "Yellow halos in vision",
      "Dry mucous membranes",
      "Headache"
    ],
    "correctAnswer": "Yellow halos in vision",
    "rationale": "Visual disturbances, including halos, are classic early signs of toxicity.",
    "clinicalPearl": "Electrolyte imbalance, especially hypokalemia, increases toxicity risk."
  },
  {
    "id": "rn-q-025",
    "scope": ["RN"],
    "medicationId": "rn-020",
    "medication": "Digoxin",
    "questionType": "multiple-choice",
    "stem": "A patient’s digoxin level is 2.4 ng/mL. What action should the nurse take?",
    "choices": [
      "Administer the next dose",
      "Notify the provider immediately",
      "Give the dose early",
      "Encourage fluids and reassess"
    ],
    "correctAnswer": "Notify the provider immediately",
    "rationale": "Therapeutic range is 0.5–2.0 ng/mL; 2.4 may indicate toxicity.",
    "clinicalPearl": "Monitor potassium closely — low potassium increases sensitivity to digoxin."
  },
  {
    "id": "rn-q-026",
    "scope": ["RN"],
    "medicationId": "rn-021",
    "medication": "Adenosine",
    "questionType": "multiple-choice",
    "stem": "What should the nurse anticipate immediately after administering adenosine for SVT?",
    "choices": [
      "Transient asystole",
      "Seizure activity",
      "Severe hypertension",
      "Respiratory distress"
    ],
    "correctAnswer": "Transient asystole",
    "rationale": "Adenosine briefly blocks conduction through the AV node, causing a short asystole.",
    "clinicalPearl": "Warn patients they may feel a sudden 'flush' or sense of doom — this is expected."
  },
  {
    "id": "rn-q-027",
    "scope": ["RN"],
    "medicationId": "rn-021",
    "medication": "Adenosine",
    "questionType": "multiple-choice",
    "stem": "Which condition is a contraindication for adenosine?",
    "choices": [
      "SVT",
      "Second-degree heart block",
      "Stable atrial flutter",
      "Hypertension"
    ],
    "correctAnswer": "Second-degree heart block",
    "rationale": "Adenosine further suppresses AV conduction, worsening heart blocks.",
    "clinicalPearl": "Only use for narrow-complex tachycardia caused by AV node reentry."
  },
   {
    "id": "rn-q-028",
    "scope": ["RN"],
    "medicationId": "rn-022",
    "medication": "Lactated Ringer's (LR)",
    "questionType": "multiple-choice",
    "stem": "Which patient would most likely benefit from Lactated Ringer’s?",
    "choices": [
      "Client with severe liver failure",
      "Client with blood loss from trauma",
      "Client with increased intracranial pressure",
      "Client with end-stage kidney disease"
    ],
    "correctAnswer": "Client with blood loss from trauma",
    "rationale": "LR is an isotonic fluid used for volume replacement, common in trauma and OR settings.",
    "clinicalPearl": "Avoid LR in liver failure because lactate must be metabolized in the liver."
  },
  {
    "id": "rn-q-029",
    "scope": ["RN"],
    "medicationId": "rn-023",
    "medication": "Normal Saline (NS)",
    "questionType": "multiple-choice",
    "stem": "Which situation warrants cautious use or avoidance of normal saline?",
    "choices": [
      "Hypotension",
      "Hyponatremia",
      "Fluid overload and heart failure",
      "Vomiting and dehydration"
    ],
    "correctAnswer": "Fluid overload and heart failure",
    "rationale": "NS expands extracellular volume and may worsen pulmonary edema in CHF patients.",
    "clinicalPearl": "Isotonic fluids stay in the vascular space — monitor for crackles and dyspnea."
  },
  {
    "id": "rn-q-030",
    "scope": ["RN"],
    "medicationId": "rn-024",
    "medication": "D5W (5% Dextrose in Water)",
    "questionType": "multiple-choice",
    "stem": "Which statement is correct about D5W administration?",
    "choices": [
      "It remains entirely in the vascular space",
      "It is contraindicated in increased intracranial pressure",
      "It is ideal for rapid resuscitation in hypovolemic shock",
      "It is a replacement for electrolyte loss"
    ],
    "correctAnswer": "It is contraindicated in increased intracranial pressure",
    "rationale": "D5W becomes hypotonic in the body and increases cerebral edema.",
    "clinicalPearl": "D5W is considered isotonic in the bag, hypotonic in the body."
  },
  {
    "id": "rn-q-031",
    "scope": ["RN"],
    "medicationId": "rn-025",
    "medication": "0.45% Normal Saline (1/2 NS)",
    "questionType": "multiple-choice",
    "stem": "A provider orders 1/2 NS for a patient. Which condition would make the nurse question the order?",
    "choices": [
      "Dehydration",
      "Diabetic ketoacidosis",
      "Increased intracranial pressure",
      "Hypernatremia"
    ],
    "correctAnswer": "Increased intracranial pressure",
    "rationale": "Hypotonic fluids move water into cells and can worsen cerebral swelling.",
    "clinicalPearl": "1/2 NS is used for intracellular dehydration — NOT when brain swelling is present."
  },
  {
    "id": "rn-q-032",
    "scope": ["RN"],
    "medicationId": "rn-026",
    "medication": "D10W (10% Dextrose in Water)",
    "questionType": "multiple-choice",
    "stem": "Which situation is the most appropriate indication for D10W?",
    "choices": [
      "Severe hyponatremia",
      "Cerebral edema",
      "Hypoglycemia unresponsive to D50",
      "Maintenance IV fluid for NPO clients"
    ],
    "correctAnswer": "Hypoglycemia unresponsive to D50",
    "rationale": "D10W is used when immediate glucose replacement is needed but D50 is unsafe or unavailable.",
    "clinicalPearl": "Hypertonic fluids pull fluid into the vascular space — monitor for fluid overload."
  },
  {
    "id": "rn-q-033",
    "scope": ["RN"],
    "medicationId": "rn-027",
    "medication": "Albumin",
    "questionType": "multiple-choice",
    "stem": "Which assessment is most important before administering IV albumin?",
    "choices": [
      "Blood glucose level",
      "Liver function tests",
      "Lung sounds and signs of fluid overload",
      "Deep tendon reflexes"
    ],
    "correctAnswer": "Lung sounds and signs of fluid overload",
    "rationale": "Albumin rapidly expands plasma volume; assess for pulmonary edema risk.",
    "clinicalPearl": "Albumin pulls fluid into the vascular space — watch for crackles and dyspnea."
  },
  {
    "id": "rn-q-034",
    "scope": ["RN"],
    "medicationId": "rn-028",
    "medication": "Pyridostigmine",
    "questionType": "multiple-choice",
    "stem": "A patient taking pyridostigmine reports increased muscle weakness, drooling, and diarrhea. What is the priority action?",
    "choices": [
      "Administer an additional dose",
      "Hold the dose and notify the provider",
      "Encourage oral fluids",
      "Administer acetaminophen"
    ],
    "correctAnswer": "Hold the dose and notify the provider",
    "rationale": "These symptoms suggest cholinergic crisis due to excessive dosing.",
    "clinicalPearl": "Myasthenic crisis = too little med; cholinergic crisis = too much med."
  },
  {
    "id": "rn-q-035",
    "scope": ["RN"],
    "medicationId": "rn-028",
    "medication": "Pyridostigmine",
    "questionType": "select-all-that-apply",
    "stem": "What should the nurse include in teaching for pyridostigmine? (Select all that apply.)",
    "choices": [
      "Take medication at the same time every day",
      "Report difficulty swallowing",
      "Expect blurred vision as normal",
      "Rise slowly to avoid dizziness",
      "Maintain a medication journal"
    ],
    "correctAnswer": [
      "Take medication at the same time every day",
      "Report difficulty swallowing",
      "Rise slowly to avoid dizziness"
    ],
    "rationale": "Consistent dosing maintains symptom control; dysphagia signals crisis; dizziness relates to autonomic effects.",
    "clinicalPearl": "Timing doses around meals helps reduce aspiration risk in MG."
  },
  {
    "id": "rn-q-036",
    "scope": ["RN"],
    "medicationId": "rn-029",
    "medication": "Neostigmine",
    "questionType": "multiple-choice",
    "stem": "What finding indicates a therapeutic response to neostigmine?",
    "choices": [
      "Improved swallowing and muscle strength",
      "Decreased heart rate to 50 bpm",
      "New onset of diarrhea",
      "Severe abdominal pain"
    ],
    "correctAnswer": "Improved swallowing and muscle strength",
    "rationale": "Neostigmine increases neuromuscular function by improving acetylcholine availability.",
    "clinicalPearl": "Assess respiratory function — improving ventilation is a primary goal."
  },
  {
    "id": "rn-q-037",
    "scope": ["RN"],
    "medicationId": "rn-030",
    "medication": "Donepezil",
    "questionType": "multiple-choice",
    "stem": "Which symptom would require immediate reporting in a patient taking donepezil?",
    "choices": [
      "Mild headache",
      "Increased urination",
      "Dark, tarry stools",
      "Dry mouth"
    ],
    "correctAnswer": "Dark, tarry stools",
    "rationale": "Donepezil increases gastric acid and can lead to GI bleeding.",
    "clinicalPearl": "Monitor for GI upset and bleeding — aspirin/NSAIDs increase risk."
  },
  {
    "id": "rn-q-038",
    "scope": ["RN"],
    "medicationId": "rn-030",
    "medication": "Donepezil",
    "questionType": "multiple-choice",
    "stem": "How long does it typically take for donepezil to reach steady-state therapeutic effect?",
    "choices": [
      "48 hours",
      "7 days",
      "15 days",
      "3 months"
    ],
    "correctAnswer": "15 days",
    "rationale": "Donepezil requires time to reach steady state due to long half-life.",
    "clinicalPearl": "Caregiver education is critical — expectations must be realistic."
  },
  {
    "id": "rn-q-039",
    "scope": ["RN"],
    "medicationId": "rn-031",
    "medication": "Donepezil (transdermal)",
    "questionType": "select-all-that-apply",
    "stem": "Which instructions should be included for donepezil transdermal patch use? (Select all that apply.)",
    "choices": [
      "Apply to clean, dry, hairless skin",
      "Rotate sites to prevent irritation",
      "Fold used patches with sticky sides together",
      "Cut patches for dose adjustment",
      "Remove old patch before applying new one"
    ],
    "correctAnswer": [
      "Apply to clean, dry, hairless skin",
      "Rotate sites to prevent irritation",
      "Fold used patches with sticky sides together",
      "Remove old patch before applying new one"
    ],
    "rationale": "Patch use requires skin care, disposal safety, and removal of previous dose to prevent toxicity.",
    "clinicalPearl": "Never cut transdermal patches — dosing becomes unpredictable."
  },
  {
    "id": "rn-q-040",
    "scope": ["RN"],
    "medicationId": "rn-032",
    "medication": "Galantamine",
    "questionType": "multiple-choice",
    "stem": "Which adverse effect would be most concerning in a patient taking galantamine?",
    "choices": [
      "Constipation",
      "Severe skin rash",
      "Dry mouth",
      "Mild tremors"
    ],
    "correctAnswer": "Severe skin rash",
    "rationale": "Galantamine has rare hypersensitivity risk; rash may indicate Stevens-Johnson Syndrome.",
    "clinicalPearl": "Stop medication and notify provider immediately if rash occurs."
  },
  {
    "id": "rn-q-041",
    "scope": ["RN"],
    "medicationId": "rn-033",
    "medication": "Rivastigmine",
    "questionType": "multiple-choice",
    "stem": "What teaching is most important for a patient taking rivastigmine?",
    "choices": [
      "Take with antacids to reduce GI upset",
      "Report urinary retention immediately",
      "Monitor for cholinergic side effects like bradycardia",
      "Avoid potassium-rich foods"
    ],
    "correctAnswer": "Monitor for cholinergic side effects like bradycardia",
    "rationale": "As a cholinergic enhancer, rivastigmine may cause bradycardia and syncope.",
    "clinicalPearl": "Cholinergic symptoms = SLUDGE: salivation, lacrimation, urination, diarrhea, GI upset, emesis."
  },
   {
    "id": "rn-q-042",
    "scope": ["RN"],
    "medicationId": "rn-034",
    "medication": "Memantine",
    "questionType": "multiple-choice",
    "stem": "A patient taking memantine reports severe nausea, vomiting, and weight loss. What is the nurse’s priority action?",
    "choices": [
      "Offer small frequent meals",
      "Hold the dose and notify the provider",
      "Encourage fluid intake",
      "Administer an antiemetic"
    ],
    "correctAnswer": "Hold the dose and notify the provider",
    "rationale": "These symptoms can indicate GI complications, including possible upper GI bleeding or intolerance.",
    "clinicalPearl": "Memantine may worsen GI symptoms in susceptible patients — monitor closely early in therapy."
  },
  {
    "id": "rn-q-043",
    "scope": ["RN"],
    "medicationId": "rn-034",
    "medication": "Memantine",
    "questionType": "select-all-that-apply",
    "stem": "Which assessments are most important when monitoring memantine therapy? (Select all that apply.)",
    "choices": [
      "Cognitive status",
      "Weight and appetite",
      "Liver function",
      "Renal function",
      "Blood glucose levels"
    ],
    "correctAnswer": [
      "Cognitive status",
      "Weight and appetite",
      "Renal function"
    ],
    "rationale": "Memantine is eliminated renally and affects cognitive function and appetite.",
    "clinicalPearl": "Baseline and ongoing cognitive assessments help determine therapeutic effectiveness."
  },
  {
    "id": "rn-q-044",
    "scope": ["RN"],
    "medicationId": "rn-035",
    "medication": "Benztropine",
    "questionType": "multiple-choice",
    "stem": "Which teaching point is most important for a patient taking benztropine?",
    "choices": [
      "Avoid high-protein meals",
      "Report heat intolerance or fever",
      "Expect watery diarrhea",
      "Take with grapefruit juice"
    ],
    "correctAnswer": "Report heat intolerance or fever",
    "rationale": "Anticholinergic medications decrease sweating and can cause life-threatening hyperthermia.",
    "clinicalPearl": "Avoid strenuous activity in hot environments — heat stroke risk."
  },
  {
    "id": "rn-q-045",
    "scope": ["RN"],
    "medicationId": "rn-036",
    "medication": "Trihexyphenidyl",
    "questionType": "multiple-choice",
    "stem": "Which adverse effect requires priority intervention with trihexyphenidyl?",
    "choices": [
      "Constipation",
      "Dry mouth",
      "Acute urinary retention",
      "Blurred vision"
    ],
    "correctAnswer": "Acute urinary retention",
    "rationale": "Anticholinergic medications can cause retention requiring urgent intervention.",
    "clinicalPearl": "Increased fall risk due to blurred vision and dizziness — safety precautions needed."
  },
  {
    "id": "rn-q-046",
    "scope": ["RN"],
    "medicationId": "rn-037",
    "medication": "Carbidopa/Levodopa",
    "questionType": "multiple-choice",
    "stem": "A patient taking carbidopa/levodopa develops involuntary facial grimacing and lip smacking. What is the best action?",
    "choices": [
      "Encourage fluid intake",
      "Expect the symptom; this is normal",
      "Notify the provider immediately",
      "Hold all future doses permanently"
    ],
    "correctAnswer": "Notify the provider immediately",
    "rationale": "These symptoms indicate dyskinesias, which may require dose adjustment.",
    "clinicalPearl": "Most common long-term complication of levodopa therapy is motor fluctuation and dyskinesia."
  },
  {
    "id": "rn-q-047",
    "scope": ["RN"],
    "medicationId": "rn-037",
    "medication": "Carbidopa/Levodopa",
    "questionType": "select-all-that-apply",
    "stem": "What should be included in patient teaching for carbidopa/levodopa? (Select all that apply.)",
    "choices": [
      "Avoid high-protein meals",
      "Change positions slowly",
      "Report dark urine as a medical emergency",
      "Expect improvement immediately within 24 hours",
      "Monitor for involuntary movements"
    ],
    "correctAnswer": [
      "Avoid high-protein meals",
      "Change positions slowly",
      "Monitor for involuntary movements"
    ],
    "rationale": "Protein competes with levodopa absorption; orthostatic hypotension is common; dyskinesia signals toxicity.",
    "clinicalPearl": "Urine and sweat may darken harmlessly — this is expected."
  },
  {
    "id": "rn-q-048",
    "scope": ["RN"],
    "medicationId": "rn-038",
    "medication": "Pramipexole",
    "questionType": "multiple-choice",
    "stem": "Which patient education point is most important for pramipexole?",
    "choices": [
      "Take only at bedtime",
      "Risk of sudden daytime sleep attacks",
      "Expect rapid heart rate",
      "Report mild nausea as an emergency"
    ],
    "correctAnswer": "Risk of sudden daytime sleep attacks",
    "rationale": "Pramipexole may cause sudden sleepiness, posing safety risks.",
    "clinicalPearl": "Avoid driving or hazardous activities until response is known."
  },
  {
    "id": "rn-q-049",
    "scope": ["RN"],
    "medicationId": "rn-039",
    "medication": "Bromocriptine",
    "questionType": "multiple-choice",
    "stem": "Which lab abnormality would be most concerning for a patient on bromocriptine?",
    "choices": [
      "Elevated liver enzymes",
      "Elevated potassium",
      "Low sodium",
      "Low LDL cholesterol"
    ],
    "correctAnswer": "Elevated liver enzymes",
    "rationale": "Bromocriptine is associated with hepatotoxicity — monitor liver function.",
    "clinicalPearl": "Assess for jaundice, dark urine, and RUQ abdominal pain."
  },
  {
    "id": "rn-q-050",
    "scope": ["RN"],
    "medicationId": "rn-040",
    "medication": "Apomorphine",
    "questionType": "multiple-choice",
    "stem": "Why is routine EKG monitoring recommended for patients taking apomorphine?",
    "choices": [
      "Hypotension risk",
      "Severe hypertension is common",
      "QT interval prolongation",
      "Increased oxygen demand"
    ],
    "correctAnswer": "QT interval prolongation",
    "rationale": "Apomorphine carries a risk of ventricular dysrhythmias from prolonged QT.",
    "clinicalPearl": "Avoid other QT-prolonging drugs when possible."
  },
  {
    "id": "rn-q-051",
    "scope": ["RN"],
    "medicationId": "rn-041",
    "medication": "Ropinirole",
    "questionType": "multiple-choice",
    "stem": "What symptom should be reported immediately for a patient taking ropinirole?",
    "choices": [
      "Dry mouth",
      "Peripheral edema",
      "Mild fatigue",
      "Constipation"
    ],
    "correctAnswer": "Peripheral edema",
    "rationale": "Ropinirole may cause fluid retention and cardiac complications.",
    "clinicalPearl": "Monitor for heart failure in patients with cardiovascular disease."
  }
]

